Abbott, a global healthcare leader, focused on creating life-changing technologies that help people lead fuller and healthier lives, has received the 2020 Prix Galien USA Award for Best Medical Technology for its MitraClip System, the minimally invasive mitral valve repair device. The award recognizes excellence in scientific innovation that improves the state of humankind. MitraClip was selected from a field of 17 other medical technology nominees. This is the second year in a row that an Abbott medical device has been awarded the top prize by Prix Galien – Abbott’s FreeStyle Libre 14 day system, the world-leading1 continuous glucose monitoring technology for people with diabetes, received the award for Best Medical Technology in 2019.
“MitraClip is a first-of-its-kind, life-saving device that has transformed the lives of more than 100,000 people living with leaky mitral valves, many of whom were not treatable with open-heart mitral valve surgery – leaving them with few to no options,” said Michael Dale, senior vice president of Abbott’s structural heart business. “We are honored by this prestigious recognition by the Galien Foundation – a testament to our relentless pursuit to develop innovative treatment options for people living with structural heart conditions that allow them to live better, healthier lives.”
Abbott’s newest rapid Covid-19 test, BinaxNOW Covid-19 Ag Card, was recognized as a top innovation by the Chicago Innovation Awards. Abbott’s ID NOW Covid-19 rapid molecular test was recognized by ChicagoInno as a 2020 Inno on Fire winner.
Abbott’s smaller-than-a-pea, innovative device, Amplatzer Piccolo Occluder, which treats preemie and newborn babies with an opening in their hearts, received an Edison Award for its human-centered design in prenatal and infant care and was also recognized in the R&D 100 Awards, which highlights the most prestigious innovations and revolutionary advancements in science and technology.
Abbott was recognized as Fast Company’s “World Changing Company of the Year” for its Piccolo innovation, its work advancing the careers of underrepresented people in STEM, initiatives to fight malaria around the world, and for the company’s Covid-19 tests.
Abbott was also named to Fortune’s 2020 “Change the World” list to expand access to quality primary care and diagnostic testing in Rwanda and advance innovative testing to confront the Covid-19 pandemic.
Backed by more than 16 years of clinical experience and proven safety, effectiveness, and durability of clinical outcomes, MitraClip is a small, clip-like device that repairs both primary and secondary mitral regurgitation (MR) without the need for open-heart surgery. The proven safe, minimally invasive procedure restores the mitral valve’s proper functioning and provides almost immediate symptom relief. MitraClip patients are generally discharged from the hospital within two days, allowing them to return to their regular lives much faster than open-heart surgery. MitraClip is approved in more than 75 countries worldwide, spanning regions in Asia, Africa, Europe, the Americas, and Australia.
ID NOW Covid-19 and BinaxNOW Covid-19 Ag Card have been authorized by FDA under an EUA (and have not been FDA cleared or approved) for use by authorized laboratories only to detect nucleic acid or proteins from SARS-CoV-2, and not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics to detect and diagnose Covid-19.